BR112014001104A2 - anticorpos monoclonais antifator xii/xiia inibitório e seus usos - Google Patents

anticorpos monoclonais antifator xii/xiia inibitório e seus usos

Info

Publication number
BR112014001104A2
BR112014001104A2 BR112014001104A BR112014001104A BR112014001104A2 BR 112014001104 A2 BR112014001104 A2 BR 112014001104A2 BR 112014001104 A BR112014001104 A BR 112014001104A BR 112014001104 A BR112014001104 A BR 112014001104A BR 112014001104 A2 BR112014001104 A2 BR 112014001104A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
factor xii
inhibitory anti
xiia
inhibitory
Prior art date
Application number
BR112014001104A
Other languages
English (en)
Other versions
BR112014001104B1 (pt
Inventor
Nash Andrew
Panousis Con
Nolte Marc
Wilson Michael
Schmidbauer Stefan
Rayzman Veronika
Original Assignee
Csl Behring Gmbh
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11175105A external-priority patent/EP2548892A1/en
Application filed by Csl Behring Gmbh, Csl Ltd filed Critical Csl Behring Gmbh
Publication of BR112014001104A2 publication Critical patent/BR112014001104A2/pt
Publication of BR112014001104B1 publication Critical patent/BR112014001104B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)

Abstract

resumo patente de invenção: "anticorpos monoclonais antifator xi-i/xiia inibitório e seus usos". a presente invenção refere-se aos anticorpos antifator xii/fxiia inibitórios e métodos de seus usos.
BR112014001104-4A 2011-07-22 2012-07-20 Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica BR112014001104B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161510801P 2011-07-22 2011-07-22
EP11175105A EP2548892A1 (en) 2011-07-22 2011-07-22 Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
EP11175105.3 2011-07-22
US61/510,801 2011-07-22
EP12153310 2012-01-31
EP12153310.3 2012-01-31
PCT/EP2012/064322 WO2013014092A1 (en) 2011-07-22 2012-07-20 Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Publications (2)

Publication Number Publication Date
BR112014001104A2 true BR112014001104A2 (pt) 2017-12-12
BR112014001104B1 BR112014001104B1 (pt) 2022-12-06

Family

ID=47600530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001104-4A BR112014001104B1 (pt) 2011-07-22 2012-07-20 Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica

Country Status (13)

Country Link
US (5) US9518127B2 (pt)
EP (1) EP2734552A1 (pt)
JP (1) JP6253578B2 (pt)
KR (1) KR102042982B1 (pt)
CN (1) CN103687878B (pt)
AU (1) AU2012289001B2 (pt)
BR (1) BR112014001104B1 (pt)
CA (1) CA2841185C (pt)
HK (1) HK1198334A1 (pt)
IL (2) IL230564B2 (pt)
MX (1) MX347454B (pt)
RU (1) RU2660370C2 (pt)
WO (1) WO2013014092A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001104B1 (pt) * 2011-07-22 2022-12-06 Csl Behring Gmbh Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014135694A1 (en) * 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
WO2014207199A1 (en) 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
ES2886859T3 (es) 2014-06-18 2021-12-21 Csl Behring Gmbh Terapia usando un inhibidor del factor xii en un trastorno neurotraumático
NZ733580A (en) * 2015-01-02 2024-02-23 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
CA2993026A1 (en) * 2015-07-21 2017-01-26 Dyax Corp. A monoclonal antibody inhibitor of factor xiia
EP3405498A1 (en) * 2016-01-22 2018-11-28 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
WO2017173494A1 (en) 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
EP3723804A4 (en) * 2017-12-15 2021-10-20 CSL Limited USE OF AN FXIIA INHIBITOR IN THE TREATMENT OF RENAL FIBROSIS AND / OR CHRONIC RENAL DISEASE
JP2021527424A (ja) * 2018-06-19 2021-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
WO2021108862A1 (en) * 2019-12-03 2021-06-10 CSL Innovation Pty Ltd Use of an anti-factor xii antibody for the treatment or prevention of hereditary angioedema
US20230295343A1 (en) * 2020-06-16 2023-09-21 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
MX2022016365A (es) * 2020-07-03 2023-01-30 CSL Innovation Pty Ltd Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901859D0 (en) * 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20040077538A1 (en) 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609016T3 (es) * 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
CA2502490A1 (en) * 2002-11-08 2004-05-27 Hematech, Llc Transgenic ungulates having reduced prion protein activity and uses thereof
BR0317404A (pt) * 2002-12-20 2005-11-16 Axis Shield Diagnostics Ltd Variantes do fator xiia
GB0229837D0 (en) * 2002-12-20 2003-01-29 Axis Shield Diagnostics Ltd Variants of activated factor XII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
CA2535859A1 (en) * 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
WO2005024044A2 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
ES2387312T3 (es) 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8119137B2 (en) 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
EP2526962B1 (en) 2007-02-12 2019-08-14 CSL Behring GmbH Therapeutic application of Kazal-type serine protease inhibitors
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
US8114968B2 (en) * 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
KR20110089185A (ko) * 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
ES2688093T3 (es) * 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
WO2012094587A1 (en) * 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
BR112014001104B1 (pt) * 2011-07-22 2022-12-06 Csl Behring Gmbh Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica

Also Published As

Publication number Publication date
IL230564A0 (en) 2014-03-31
JP6253578B2 (ja) 2017-12-27
CA2841185C (en) 2021-05-25
US10513560B2 (en) 2019-12-24
IL230564B2 (en) 2023-09-01
JP2014523253A (ja) 2014-09-11
KR20140054112A (ko) 2014-05-08
US20140199361A1 (en) 2014-07-17
US20200062863A1 (en) 2020-02-27
AU2012289001A1 (en) 2013-05-02
CN103687878B (zh) 2018-01-09
KR102042982B1 (ko) 2019-11-11
IL291613A (en) 2022-05-01
RU2660370C2 (ru) 2018-07-05
CN103687878A (zh) 2014-03-26
IL230564B1 (en) 2023-05-01
MX2014000363A (es) 2014-03-27
US20180134806A1 (en) 2018-05-17
EP2734552A1 (en) 2014-05-28
US9856325B2 (en) 2018-01-02
RU2014106652A (ru) 2015-08-27
HK1198334A1 (zh) 2015-04-02
US20170121423A1 (en) 2017-05-04
US9856326B2 (en) 2018-01-02
US9518127B2 (en) 2016-12-13
WO2013014092A1 (en) 2013-01-31
AU2012289001B2 (en) 2016-03-03
US20170137536A1 (en) 2017-05-18
NZ619385A (en) 2016-07-29
US11345759B2 (en) 2022-05-31
CA2841185A1 (en) 2013-01-31
BR112014001104B1 (pt) 2022-12-06
MX347454B (es) 2017-04-27

Similar Documents

Publication Publication Date Title
BR112014001104A2 (pt) anticorpos monoclonais antifator xii/xiia inibitório e seus usos
CY1123145T1 (el) Anti-cd40 αντισωματα
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
UY34343A (es) Proteinas de unión al antígeno cd27l
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
CR20110646A (es) Anticuerpo anti-axl
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
TR201910721T4 (tr) İnsan OX40'a yönelik spesifisiteye sahip olan antikor molekülleri.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UY34558A (es) Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
BR112014009866A2 (pt) formulações de anticorpos e métodos
CO6890074A2 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
GEP20186885B (en) Novel compounds
DK2552963T3 (da) Humaniserede antistoffer mod CXCR4 til behandling af cancer
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
GB201109238D0 (en) Antibodies
BR112013022052A2 (pt) ligantes antagonísticos de dr3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.